Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis
- PMID: 32565110
- DOI: 10.1016/j.clbc.2020.04.012
Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis
Abstract
Purpose: Oncotype DX (ODX) predicts breast cancer recurrence risk, guiding the choice of adjuvant treatment. In many countries, access to the test is not always available. We used correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC), and recurrence score (RS) assessed by ODX to develop a decision supporting system for clinical use.
Patients and methods: Breast cancer patients who underwent ODX testing between 2014 and 2018 were retrospectively included in the study. The data selected for analysis were age, menopausal status, and pathologic and IHC features. IHC was performed with standardized quantitative methods. The data set was split into two subsets: 70% for the training set and 30% for the internal validation set. Statistically significant features were included in logistic models to predict RS ≤ 25 or ≤ 20. Another set was used for external validation to test reproducibility of prediction models.
Results: The internal set included 407 patients. Mean (range) age was 53.7 (31-80) years, and 222 patients (54.55%) were > 50 years old. ODX results showed 67 patients (16.6%) had RS between 0 and 10, 272 patients between 11 and 25 (66.8%), and 68 patients > 26 (16.6%). Logistic regression analysis showed that RS score (for threshold ≤ 25) was significantly associated with estrogen receptor (P = .004), progesterone receptor (P < .0001), and Ki-67 (P < .0001). Generalized linear regression resulted in a model that had an area under the receiver operating characteristic curve (AUC) of 92.2 (sensitivity 84.2%, specificity 80.1%) and that was well calibrated. The external validation set (183 patients) analysis confirmed the model performance, with an AUC of 82.3 and a positive predictive value of 91%. A nomogram was generated for further prospective evaluation to predict RS ≤ 25.
Conclusion: RS was related to quantitative IHC in patients with RS ≤ 25, with a good performance of the statistical model in both internal and external validation. A nomogram for enhancing clinical approach in a cost-effective manner was developed. Prospective studies must test this application in clinical practice.
Keywords: Adjuvant chemotherapy; Breast cancer; Decision supporting system; Health costs; Quantitative IHC.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Nomogram Development for Assessing Oncotype DX Recurrence Scores in Breast Cancer: A Chinese Population Study.Cancer Med. 2025 Mar;14(6):e70818. doi: 10.1002/cam4.70818. Cancer Med. 2025. PMID: 40116474 Free PMC article.
-
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.Breast Cancer Res Treat. 2017 May;163(1):51-61. doi: 10.1007/s10549-017-4170-3. Epub 2017 Feb 27. Breast Cancer Res Treat. 2017. PMID: 28243897 Free PMC article.
-
Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.Breast Cancer. 2024 Nov;31(6):1018-1027. doi: 10.1007/s12282-024-01616-z. Epub 2024 Jul 17. Breast Cancer. 2024. PMID: 39020239 Free PMC article.
-
The prognostic and predictive role of 21-gene recurrence scores in hormone receptor-positive early-stage breast cancer.J Surg Oncol. 2020 Aug;122(2):144-154. doi: 10.1002/jso.25952. Epub 2020 Apr 28. J Surg Oncol. 2020. PMID: 32346902 Review.
-
Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.Breast Cancer (Auckl). 2024 May 20;18:11782234241255211. doi: 10.1177/11782234241255211. eCollection 2024. Breast Cancer (Auckl). 2024. PMID: 38779417 Free PMC article. Review.
Cited by
-
What factors enhance students' achievement? A machine learning and interpretable methods approach.PLoS One. 2025 May 16;20(5):e0323345. doi: 10.1371/journal.pone.0323345. eCollection 2025. PLoS One. 2025. PMID: 40378114 Free PMC article.
-
Nomogram Development for Assessing Oncotype DX Recurrence Scores in Breast Cancer: A Chinese Population Study.Cancer Med. 2025 Mar;14(6):e70818. doi: 10.1002/cam4.70818. Cancer Med. 2025. PMID: 40116474 Free PMC article.
-
The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing.Cancers (Basel). 2023 Jan 31;15(3):903. doi: 10.3390/cancers15030903. Cancers (Basel). 2023. PMID: 36765860 Free PMC article.
-
Cerebrospinal Fluid p‑Tau181/Amyloid Beta 42 Ratio Identifies Lymphatic-Venous Anastomosis Patients Who Respond to and Benefit from the Surgery for Relief of Cognitive Impairment with a Diagnostic Accuracy of 0.744.ACS Omega. 2025 Jul 16;10(29):32029-32037. doi: 10.1021/acsomega.5c03650. eCollection 2025 Jul 29. ACS Omega. 2025. PMID: 40757274 Free PMC article.
-
Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age.Breast Cancer Res Treat. 2022 Dec;196(3):565-570. doi: 10.1007/s10549-022-06763-5. Epub 2022 Oct 21. Breast Cancer Res Treat. 2022. PMID: 36269526 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous